Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7QK | ISIN: GB0034330679 | Ticker-Symbol: DWV
Frankfurt
21.11.24
09:06 Uhr
0,112 Euro
-0,020
-15,15 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
ANGLE PLC Chart 1 Jahr
5-Tage-Chart
ANGLE PLC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1740,19014:45

Aktuelle News zur ANGLE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAngle stock surges as firm showcases new assay products2
FrAngle PLC Announces Research on HER2 Assay Kit Showcased at AACR110RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCEParsortix-based HER2 kit being developed to provide an optimised, easily implemented...
► Artikel lesen
FrAngle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR114CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ANGLE...
► Artikel lesen
ANGLE Aktie jetzt für 0€ handeln
14.11.3 Ways Investors Angle To Profit From Trump's Next Four Years1
13.11.ANGLE plc: ANGLE presents two posters at EACR96PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCETwo posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation...
► Artikel lesen
11.11.Angle notes use of Parsortix system in treatment resistance study-
11.11.Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients206ANGLE plc ("the Company")DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis...
► Artikel lesen
17.10.Angle PLC Announces Publication Demonstrates CTC Profiling Potential121PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE CANCERParsortix enriched CTCs detected at high rates in localised diseaseMulti-marker profiling of CTCs could support...
► Artikel lesen
26.09.Angle Plc reports 1H results2
26.09.Angle PLC Announces 100th Publication Supporting Parsortix System Use224GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repairANGLE plc (AIM:AGL)(OTCQX:ANPCY)...
► Artikel lesen
26.09.Angle PLC Announces Half-year Report160Interim Results for the six months ended 30 June 2024LARGE PHARMA STRATEGY IMPLEMENTED SUCCESSFULLYThree Large Pharma contracts secured each with substantial revenue potentialStrategic decision post...
► Artikel lesen
23.09.ANGLE Enters Agreement With NuProbe; Gets Worldwide Licence Option For NGS Panel-
23.09.Angle PLC Announces Exclusive agreement for DNA NGS panel182ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBEOption for exclusive licence to highly sensitive NGS assay for use with CTCs and dual analysis of CTCs with ctDNACombining the...
► Artikel lesen
19.09.IN BRIEF: Angle celebrates agreement with Recursion Pharmaceuticals3
19.09.Angle signs new agreement US biotech Recursion7
19.09.Angle PLC Announces Agreement with Recursion Pharmaceuticals255New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating...
► Artikel lesen
17.09.Angle PLC Announces Notice of Interim Results and Webcast219Notice of Interim Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / September 17, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour...
► Artikel lesen
23.08.IN BRIEF: Angle hails publication of research data in science journal1
22.08.Angle PLC - Data Supporting FDA Approval Published in Journal223DATA SUPPORTING FDA APPROVAL PUBLISHED IN HIGH-IMPACT JOURNALPublication of results from ANGLE's Parsortix PC1 system validates use of Parsortix System for CTC isolation and harvest in metastatic breast...
► Artikel lesen
18.07.Angle PLC Announces Standard Form for Notification of Major Holdings217GUILDFORD, SURREY / ACCESSWIRE / July 18, 2024 / TR-1: TR-1:Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft...
► Artikel lesen
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1